Compugen (CGEN) 24th Annual Needham Virtual Healthcare Conference summary

Company overview and platform

• Focuses on immuno-oncology using a proprietary computational platform, Unigen, to discover novel drug targets validated through pharma partnerships and clinical progress.

• Pipeline includes two fully owned assets (COM701 and COM902) and several undisclosed early-stage assets, with a cash runway into 2027.

• Collaborates with Ultima Genomics to enhance its AI-driven discovery platform by sequencing patient tumor samples and identifying novel targets.

Pipeline highlights and clinical strategy

• COM701, a first-in-class anti-PVRIG antibody, shows differentiated activity and safety in platinum-resistant ovarian cancer, prompting a move to platinum-sensitive maintenance settings.

• Adaptive trial for COM701 in platinum-sensitive ovarian cancer starts in Q2 2024, with results expected in H2 2026; aims to extend progression-free survival by three months.

• COM902, a best-in-class anti-TIGIT antibody with reduced FC receptor binding, is positioned for better safety and efficacy compared to FC-active competitors.

• AstraZeneca is advancing a TIGIT/PD-1 bispecific (rilvegostomig) using COM902 in eight Phase 3 trials, with potential blockbuster sales and milestone/royalty payments.

Collaborations and financials

• Gilead licensed a novel cytokine-targeting antibody (GS-0321/COM503), with $90 million received to date and up to $758 million in milestones plus royalties; Compugen leads early clinical development.

• Ongoing collaborations leverage computational insights to identify resistance mechanisms and novel targets, feeding the pipeline for future clinical candidates.